Genetic modulation of oral anticoagulation with warfarin

M. Margaglione, D. Colaizzo, G. D'Andrea, V. Brancaccio, A. Ciampa, E. Grandone, G. Di Minno

Research output: Contribution to journalArticle

Abstract

Cytochrome P450 CYP2C9 gene variants have been associated with hyperresponsiveness to small doses of warfarin and a higher bleeding complication rate. The aim of this study was to investigate whether CYP2C9 gene variants affect doses of drug prescribed to acquire the target anticoagulation intensity and the occurrence of bleeding complications. In a cohort of 180 patients followed up at one specialized clinic from the start of the anticoagulation with warfarin, we have investigated whether CYP2C9 gene variants have affected doses of drug prescribed to acquire the target anticoagulation intensity and the incidence of bleeding complications. The adjusted dose required of warfarin was higher among patients with the CYP2C9*1 haplotype (5.6 mg) than those of patients carrying the CYP2C9*2 (4.7 mg; p = 0.007, Scheffe's test) or the CYP2C9*3 haplotype (4.0 mg; p

Original languageEnglish
Pages (from-to)775-778
Number of pages4
JournalThrombosis and Haemostasis
Volume84
Issue number5
Publication statusPublished - 2000

Keywords

  • 450 CYP2C9
  • Bleeding
  • Dose requirement
  • Polymorphisms
  • Warfarin

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Genetic modulation of oral anticoagulation with warfarin'. Together they form a unique fingerprint.

  • Cite this

    Margaglione, M., Colaizzo, D., D'Andrea, G., Brancaccio, V., Ciampa, A., Grandone, E., & Di Minno, G. (2000). Genetic modulation of oral anticoagulation with warfarin. Thrombosis and Haemostasis, 84(5), 775-778.